The Journal of Experimental Medicine
Torrey Pines Biolabs
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 14 May 2001.
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 236K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yen, J.-H.
Right arrow Articles by Goronzy, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yen, J.-H.
Right arrow Articles by Goronzy, J. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© The Rockefeller University Press, 0022-1007/2001/5/1159/ $5.00
The Journal of Experimental Medicine, Volume 193, Number 10, May 21, 2001 1159-1168


Original Article

Major Histocompatibility Complex Class I–recognizing Receptors Are Disease Risk Genes in Rheumatoid Arthritis

Jeng-Hsien Yena, Brenda E. Moorea, Takako Nakajimaa, Dirk Scholla, Daniel J. Schaidb, Cornelia M. Weyanda, and Jörg J. Goronzya
a Department of Medicine and the Department of Immunology, Mayo Clinic, Rochester, Minnesota 55905
b Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905

Correspondence to: Jörg J. Goronzy, Mayo Clinic, Guggenheim 401, 200 First St. SW, Rochester, MN 55905. Tel:507-284-1650 Fax:507-284-5045 E-mail:goronzy.jorg{at}mayo.edu.

Rheumatoid arthritis (RA) is a heterogeneous syndrome of which a subset of patients develops vascular inflammation. The genetic determinants that confer risk for rheumatoid vasculitis are not known, but patients with vascular complications are known to have an expansion of CD4+CD28null T cells, a cell population potentially involved in endothelial damage. CD4+CD28null T cell clones isolated from RA patients with vasculitis were found to express killer cell immunoglobulin–like receptors (KIRs) with the stimulatory KIR2DS2 often present in the absence of opposing inhibitory receptors with related specificities. To test the hypothesis that the KIR2DS2 gene is involved in the development of vasculitis, association studies were performed. The KIR2DS2 gene was significantly enriched among patients with rheumatoid vasculitis compared with normal individuals (odds ratio 5.56, P = 0.001) and patients with RA but no vasculitis (odds ratio 7.96, P = 0.001). Also, the distribution of human histocompatibility leukocyte antigen (HLA)-C, the putative ligand for KIRs, was significantly different in patients with rheumatoid vasculitis in comparison with the control populations. These data suggest that HLA class I–recognizing receptors and HLA class I genes are genetic risk determinants that modulate the pattern of RA expression. Specifically, KIR2DS2 in conjunction with the appropriate HLA-C ligand may have a role in vascular damage by regulating CD4+CD28null T cells.

Key Words: killer cell immunoglobulin–like receptor, T cell, genetic susceptibility, rheumatoid arthritis, vasculitis


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS